Efficacy of Carfilzomib (K), Pomalidomide (P), and Dexamethasone (d) in Heavily Pretreated Patients with Relapsed/ Refractory Multiple Myeloma (RRMM) in a Real World Setting

被引：5
|
作者：
Hobbs, Miriam [1 ]
Paludo, Jonas [1 ]
Fonder, Amie [1 ]
Abeykoon, Jithma P. [2 ]
Gertz, Morie A. [1 ]
Rajkumar, S. Vincent [1 ]
Go, Ronald S. [1 ]
Buadi, Francis K. [1 ]
Lacy, Martha Q. [1 ]
Leung, Nelson [1 ]
Dispenzieri, Angela [1 ]
Gonsalves, Wilson I. [1 ]
Dingli, David [1 ]
Hwa, Yi L. [1 ]
Kourelis, Taxiarchis [1 ]
Kyle, Robert A. [1 ]
Kumar, Shaji [1 ]
Kapoor, Prashant [1 ]
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Dept Internal Med, Rochester, MN USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3337.3337
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3337
引用
收藏
页数：6
相关论文
共 50 条
  • [1] MELFLUFEN THERAPY FOR HEAVILY PRETREATED RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS REFRACTORY TO DARATUMUMAB AND/OR POMALIDOMIDE: EARLY EFFICACY DATA (HORIZON)
    Mateos, M., V
    Oriol Rocafiguera, A.
    Rodriguez-Otero, P.
    Blade, J.
    Larocca, A.
    Moreb, S. J.
    Cavo, M.
    Mazumder, A.
    Alegre, A.
    Hassoun, H.
    Maisel, C.
    Paner, A.
    Gabrail, N.
    Halka, K.
    Zonder, J.
    Ocio, E.
    Byrne, C.
    Harmenberg, J.
    Lindberg, J.
    Nordstrom, E.
    Thuresson, S.
    Richardson, G. P.
    HAEMATOLOGICA, 2018, 103 : 32 - 32
  • [2] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2016, 128 (22)
  • [3] Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma ( RRMM) Patients
    不详
    BLOOD, 2021, 138
  • [4] Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma
    Salomon-Perzynski, Aleksander
    Walter-Croneck, Adam
    Usnarska-Zubkiewicz, Lidia
    Dytfeld, Dominik
    Zielinska, Patrycja
    Wojciechowska, Malgorzata
    Holojda, Jadwiga
    Robak, Pawel
    Pasternak, Anna
    Knopinska-Posluszny, Wanda
    Hawrylecka, Dorota
    Wojtowicz, Marcin
    Szeremet, Agnieszka
    Osowiecki, Michal
    Mordak-Domagala, Monika
    Zaucha, Jan Maciej
    Giannopoulos, Krzysztof
    Warzocha, Krzysztof
    Jamroziak, Krzysztof
    ADVANCES IN MEDICAL SCIENCES, 2019, 64 (02): : 349 - 355
  • [5] Metronomic therapy for heavily pretreated relapsed/refractory multiple myeloma (RRMM).
    Papanikolaou, Xenofon
    Szymonifka, Jackie
    Mitchell, Alan
    Keller, Jason
    Heuck, Christoph Johann
    Waheed, Sarah
    Usmani, Saad Zafar
    Nair, Bijay
    Van Rhee, Frits
    Medlin, Stephen Charles
    Bailey, Clyde
    Petty, Nathan
    Hoering, Antje
    Crowley, John
    Barlogie, Bart
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [7] A REAL-WORLD EFFICACY AND SAFETY ANALYSIS OF CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE (KRD) COMBINATION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Caratozzolo, I.
    Tacchetti, P.
    Zambello, R.
    Pantani, L.
    Antonioli, E.
    Mancuso, K.
    Buda, G.
    Rocchi, S.
    Canepa, L.
    Rizzello, I.
    Gamberi, B.
    Barila, G.
    Testoni, N.
    Marzocchi, G.
    Zamagni, E.
    Cavo, M.
    HAEMATOLOGICA, 2019, 104 : 66 - 66
  • [8] Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Blade, Joan
    Cavo, Michele
    Rodriguez-Otero, Paula
    Leleu, Xavier
    Nadeem, Omar
    Hiemenz, John W.
    Hassoun, Hani
    Touzeau, Cyrille
    Alegre, Adrian
    Paner, Agne
    Maisel, Christopher
    Mazumder, Amitabha
    Raptis, Anastasios
    Moreb, Jan S.
    Anderson, Kenneth C.
    Laubach, Jacob P.
    Thuresson, Sara
    Thuresson, Marcus
    Byrne, Catriona
    Harmenberg, Johan
    Bakker, Nicolaas A.
    Mateos, Maria-Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (07) : 757 - +
  • [9] Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Shaikh, Hira
    Lochner, Jonathan
    Friend, Reed
    Snyder, Jordan
    Davis, James
    Patrus, Gina
    Dileo, Rachel
    Ahmed, Nausheen
    Mewawalla, Prerna
    Poonsombudlert, Kittika
    Struble, Emily
    Wolcott, Allyson
    Green, Kimberly
    Sparrow, Samantha
    Mushtaq, Muhammad Umair
    Paul, Barry
    Abdallah, Al-Ola
    Strouse, Christopher
    Hashmi, Hamza
    Atrash, Shebli
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S87 - S88
  • [10] Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma
    Dima, Danai
    Davis, James A.
    Ahmed, Nausheen
    Sannareddy, Aishwarya
    Shaikh, Hira
    Mahmoudjafari, Zahra
    Khouri, Jack
    Kaur, Gurbakhash
    Strouse, Christopher
    Valent, Jason
    Larry, Anderson D., Jr.
    Anwer, Faiz
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD, 2023, 142
12345